Free Trial
NASDAQ:LGND

Ligand Pharmaceuticals (LGND) Stock Price, News & Analysis

Ligand Pharmaceuticals logo
$114.61 +0.85 (+0.75%)
As of 02:25 PM Eastern

About Ligand Pharmaceuticals Stock (NASDAQ:LGND)

Key Stats

Today's Range
$114.00
$116.70
50-Day Range
$100.19
$118.22
52-Week Range
$85.18
$129.90
Volume
54,788 shs
Average Volume
117,839 shs
Market Capitalization
$2.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$146.14
Consensus Rating
Buy

Company Overview

Ligand Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
96th Percentile Overall Score

LGND MarketRank™: 

Ligand Pharmaceuticals scored higher than 96% of companies evaluated by MarketBeat, and ranked 56th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Ligand Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Ligand Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Ligand Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Ligand Pharmaceuticals are expected to grow by 114.45% in the coming year, from $1.73 to $3.71 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ligand Pharmaceuticals is -16.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ligand Pharmaceuticals is -16.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Ligand Pharmaceuticals has a P/B Ratio of 2.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Ligand Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    6.41% of the float of Ligand Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Ligand Pharmaceuticals has a short interest ratio ("days to cover") of 9.7.
  • Change versus previous month

    Short interest in Ligand Pharmaceuticals has recently decreased by 6.50%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Ligand Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Ligand Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.41% of the float of Ligand Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Ligand Pharmaceuticals has a short interest ratio ("days to cover") of 9.7.
  • Change versus previous month

    Short interest in Ligand Pharmaceuticals has recently decreased by 6.50%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Ligand Pharmaceuticals has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Ligand Pharmaceuticals this week, compared to 6 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Ligand Pharmaceuticals insiders have bought 429.77% more of their company's stock than they have sold. Specifically, they have bought $1,156,542.00 in company stock and sold $218,310.00 in company stock.

  • Percentage Held by Insiders

    Only 7.00% of the stock of Ligand Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    91.28% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Ligand Pharmaceuticals' insider trading history.
Receive LGND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LGND Stock News Headlines

I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
Ligand Pharmaceuticals Incorporated (LGND) - Yahoo Finance
See More Headlines

LGND Stock Analysis - Frequently Asked Questions

Ligand Pharmaceuticals' stock was trading at $107.15 at the start of the year. Since then, LGND shares have increased by 7.6% and is now trading at $115.32.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced its quarterly earnings data on Thursday, May, 8th. The biotechnology company reported $1.33 EPS for the quarter, beating the consensus estimate of $1.23 by $0.10. The biotechnology company had revenue of $45.33 million for the quarter, compared to analysts' expectations of $37.84 million. Ligand Pharmaceuticals had a negative net margin of 73.07% and a negative trailing twelve-month return on equity of 7.83%.
Read the conference call transcript
.

Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ligand Pharmaceuticals investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
5/08/2025
Today
7/08/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:LGND
Employees
80
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$146.14
High Stock Price Target
$160.00
Low Stock Price Target
$135.00
Potential Upside/Downside
+28.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
65.76
P/E Growth
N/A
Net Income
-$4.03 million
Pretax Margin
-88.77%

Debt

Sales & Book Value

Annual Sales
$181.49 million
Cash Flow
$1.60 per share
Price / Cash Flow
71.31
Book Value
$43.95 per share
Price / Book
2.59

Miscellaneous

Free Float
17,943,000
Market Cap
$2.19 billion
Optionable
Optionable
Beta
0.84

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:LGND) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners